Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10979
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSeeman, Egoen
dc.contributor.authorDelmas, Pierre Den
dc.contributor.authorHanley, David Aen
dc.contributor.authorSellmeyer, Deborahen
dc.contributor.authorCheung, Angela Men
dc.contributor.authorShane, Elizabethen
dc.contributor.authorKearns, Annen
dc.contributor.authorThomas, Thierryen
dc.contributor.authorBoyd, Steven Ken
dc.contributor.authorBoutroy, Stephanieen
dc.contributor.authorBogado, Cesaren
dc.contributor.authorMajumdar, Sharmilaen
dc.contributor.authorFan, Michelleen
dc.contributor.authorLibanati, Cesaren
dc.contributor.authorZanchetta, Joseen
dc.date.accessioned2015-05-16T00:33:28Z
dc.date.available2015-05-16T00:33:28Z
dc.date.issued2010-08-01en
dc.identifier.citationJournal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research; 25(8): 1886-94en
dc.identifier.govdoc20222106en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10979en
dc.description.abstractThe intensity of bone remodeling is a critical determinant of the decay of cortical and trabecular microstructure after menopause. Denosumab suppresses remodeling more than alendronate, leading to greater gains in areal bone mineral density (aBMD). These greater gains may reflect differing effects of each drug on bone microarchitecture and strength. In a phase 2 double-blind pilot study, 247 postmenopausal women were randomized to denosumab (60 mg subcutaneous 6 monthly), alendronate (70 mg oral weekly), or placebo for 12 months. All received daily calcium and vitamin D. Morphologic changes were assessed using high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal radius and distal tibia and QCT at the distal radius. Denosumab decreased serum C-telopeptide more rapidly and markedly than alendronate. In the placebo arm, total, cortical, and trabecular BMD and cortical thickness decreased (-2.1% to -0.8%) at the distal radius after 12 months. Alendronate prevented the decline (-0.6% to 2.4%, p = .051 to <.001 versus placebo), whereas denosumab prevented the decline or improved these variables (0.3% to 3.4%, p < .001 versus placebo). Changes in total and cortical BMD were greater with denosumab than with alendronate (p < or = .024). Similar changes in these parameters were observed at the tibia. The polar moment of inertia also increased more in the denosumab than alendronate or placebo groups (p < .001). Adverse events did not differ by group. These data suggest that structural decay owing to bone remodeling and progression of bone fragility may be prevented more effectively with denosumab.en
dc.language.isoenen
dc.subject.otherAgeden
dc.subject.otherAlendronate.administration & dosage.adverse effects.pharmacologyen
dc.subject.otherAntibodies, Monoclonal.administration & dosage.adverse effects.pharmacologyen
dc.subject.otherAntibodies, Monoclonal, Humanizeden
dc.subject.otherBiological Markers.metabolismen
dc.subject.otherBone Density.drug effectsen
dc.subject.otherBone Density Conservation Agents.administration & dosage.adverse effects.pharmacologyen
dc.subject.otherBone Remodeling.drug effectsen
dc.subject.otherBone and Bones.drug effects.pathology.radiographyen
dc.subject.otherDemographyen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherMiddle Ageden
dc.subject.otherRANK Ligand.administration & dosage.adverse effects.pharmacologyen
dc.subject.otherTomography, X-Ray Computeden
dc.titleMicroarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Bone and Mineral Researchen
dc.identifier.affiliationAustin Health, University of Melbourne, Melbourne, Australiaen
dc.identifier.doi10.1002/jbmr.81en
dc.description.pages1886-94en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/20222106en
dc.type.austinJournal Articleen
local.name.researcherSeeman, Ego
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

32
checked on Dec 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.